Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2000
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for the large-scale analysis of genetic variation and function. The company's core technologies include BeadArray (fiber optic-based arrays) and Oligator (parallel DNA synthesis). As of the reporting date, the company had no commercially available products and generated revenue primarily from government grants and strategic research collaborations.
Key Financial Metrics
| Metric | 2000 | 1999 |
|---|---|---|
| Revenue | $1.31 million | $0.47 million |
| Net Loss | $(18.61) million | $(5.52) million |
| Loss from Operations | $(23.24) million | $(5.92) million |
| Research & Development Expenses | $13.55 million | $4.09 million |
| General & Administrative Expenses | $4.19 million | $1.35 million |
| Cash, Cash Equivalents & Investments | $117.10 million | $33.09 million |
| Working Capital | $126.26 million | $32.88 million |
| Accumulated Deficit | $(25.27) million | $(6.66) million |
| Stockholders' Equity | $124.10 million | $32.03 million |
Note: Revenue is primarily derived from government grants. The company recorded significant non-cash charges related to the amortization of deferred compensation ($6.80 million in 2000).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 176% to $1.31 million, driven by government grants and deferred revenue recognition from strategic partners.
- Expense Surge: Total costs and expenses increased 284% to $24.54 million. Research and Development (R&D) expenses rose 232% to $13.55 million due to increased staffing, a $1.63 million charge for in-process technology acquisition, and higher stock-based compensation.
- Capital Raise: Financing activities provided $103.3 million in 2000, primarily from the Initial Public Offering (IPO) in July 2000, compared to $28.1 million in 1999. This significantly bolstered liquidity.
- Net Loss Expansion: Net loss widened to $18.61 million from $5.52 million, reflecting the heavy investment in R&D and infrastructure ahead of commercial product launch.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Commercialization: The company expects to commercialize its first products (SNP genotyping assays) in early 2002 in partnership with Applied Biosystems.
- Profitability: Management expects to continue incurring net losses and negative cash flow for the foreseeable future as it funds R&D and commercialization efforts.
- Liquidity: With $117.1 million in cash and investments, the company believes it has sufficient capital to fund operations for at least the next 24 months.
Key Risks and Contingencies:
- Product Development: No products are currently commercially available; success depends on the successful development and market acceptance of unproven technologies.
- Partnership Dependency: Commercialization relies heavily on the partnership with Applied Biosystems. Failure of this partner to deliver instruments or market products could delay revenue.
- Manufacturing: The company has limited manufacturing experience and relies on single-source suppliers for critical components like fiber optic bundles.
- Intellectual Property: Success depends on obtaining and maintaining patent protection; competitors may design around patents or challenge their validity.
- Legal Proceedings: A lawsuit was filed in March 2001 by a former employee regarding termination; the company intends to defend vigorously.
Investor Verification Checklist
- Revenue Recognition: Verify the timing of revenue recognition for the $5.0 million in deferred revenue from Applied Biosystems under SAB 101 guidelines.
- Stock-Based Compensation: Review the valuation assumptions for the $6.8 million in non-cash compensation charges and the impact of the 2000 Stock Plan.
- Capital Expenditures: Confirm the status of the $24 million mortgage assumption and construction costs for the new San Diego facilities scheduled for 2001.
- Partnership Milestones: Monitor the progress of the Applied Biosystems collaboration, specifically the delivery of detection instruments and reagent kits.
- Regulatory and IP: Assess the status of pending patent applications and any potential challenges to the company's intellectual property portfolio.